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Introduction
The complement system can be activated by three interconnected routes, the classical, the lectin and the alternative pathways (1) . Activation of both the classical and the lectin pathways leads to the formation of the same C3 convertase, namely C4bC2a. Upon C3 cleavage C3b is generated that forms a transient complex with factor B (FB 3 ). The FB component of the pro-convertase C3bB is then cleaved by factor D (FD) to produce the alternative pathway C3 convertase, C3bBb. Hence the alternative pathway serves as an important amplification loop for both the classical and the lectin pathways, however it can be also activated on its own by the "tick-over" mechanism (1) .
Components of the lectin pathway are (at least) five different pattern recognition molecules, MBL, H-ficolin (ficolin-3), L-ficolin (ficolin-2), M-ficolin (ficolin-1), and CL-LK, three MBLassociated serine proteases, MASP-1, MASP-2, and MASP-3, and two MBL-associated proteins, MAp19 (sMAP), and MAp44 (MAP-1) (2-5). MASP-1 was shown to be the exclusive initiating enzyme during the activation of the lectin pathway (6) (7) , and together with MASP-2, they are both essential for the C4bC2a convertase formation. On the other hand the function of MASP-3 has been unclear. MASP-1 has relatively broad substrate specificity (8) and it was implicated that it has a role in several pro-inflammatory reactions (9-10) and coagulation (11) . Both MASP-1 and MASP-3
were suggested to participate in pro-FD conversion to FD (12) (13) and it was speculated that even the proenzyme form of MASP-3 might be able to perform this process (13) .
FD is a key enzyme for the alternative pathway. Its sole natural substrate is FB in complex with C3b (14) . When purified from blood only the active form can be retrieved (15) (16) , and it is accepted that FD is present predominantly in the active form in normal blood (15) , although some pro-FD was reported to be present in diisopropyl-fluorophosphate-treated human plasma (17) . It was speculated that FD might be activated before secretion by an unknown protease within the cells (18) . In most cell types, expression of natural (19) or recombinant pre-pro-FD (i.e. a construct containing a signal peptide and the putative propeptide) resulted in accumulation of the active form in the cell culture supernatant (20) although a portion of the produced FD was proenzymic (20) . On the other hand pro-FD was successfully produced in insect cells (21) . In vitro, trypsin was found to be the best activator of pro-FD, while thrombin, kallikrein and plasmin can also activate it with varying efficiencies (21) , however, the exact kinetic constants have not been determined. In MASP-1/3(-/-) mice only pro-FD was found (12) , and at first it was suggested that MASP-1 might be the enzyme responsible for pro-FD cleavage. However, reconstitution of the MASP-1/3(-/-) mouse serum with recombinant MASP-1 did not restore the alternative pathway (12) . Later MASP-3 was also implicated as a possible pro-FD activator (13) suggesting a new role for this enzyme. On the other hand alternative pathway activity was observed in MASP-1/3(-/-) human serum suggesting that neither MASP-1 nor MASP-3 is essential in pro-FD conversion to FD (22) . Nevertheless this scientific debate brought to light some questions that for a long time have seemed to be resolved (23) (24) .
Interestingly in Cfh(-/-)MASP-1/3(-/-) mice (deficient for factor H, MASP-1 and MASP-3)
uncontrolled alternative pathway activation was present just like in Cfh(-/-) mice, suggesting that MASP-1 and -3 are not required for alternative pathway activity in Cfh(-/-) mice (25) . In summary, the exact roles of MASPs in pro-FD activation have not been clarified yet, and additionally, we cannot exclude the possibility that significant differences may exist between human and mouse complement regarding pro-FD activation.
In this study we aimed to clarify the role of MASPs in pro-FD activation in human blood.
For this purpose we determined pro-FD cleavage rates using i) purified enzymes, ii) normal human serum and plasma in the absence and presence of specific MASP inhibitors and iii) normal human plasma with exogenous MASPs added. Our quantitative data (in combination) rule out all MASP proenzymes, as well as active MASP-1 and MASP-2 as direct pro-FD activators in resting blood, however, active MASP-3 is a likely physiological activator. The term "resting blood" in this paper refers to blood, in which neither the coagulation system nor the complement system is activated above the baseline level.
Proteins and reagents
Wild-type recombinant MASP-1, MASP-2, and MASP-3 catalytic fragments encompassing the CCP1-CCP2-SP domains (MASP-1cf, MASP-2cf, and MASP-3cf) were produced as described (26) (27) 7) . MASP-1cf and MASP-2cf are obtained as active enzymes, while MASP-3cf is produced as a zymogen. Zymogen MASP-3cf was further purified on a YMC-Q30 (YMC Europe GmbH) anionexchange column (16 mm × 100 mm) by applying a 20-column-volume (CV) gradient of 60-200 mM NaCl in 10 mM Tris-HCl pH=8.2. Active MASP-3cf was produced from the zymogen by cleavage using MASP-1cf, and then MASP-1cf was chromatographically removed as described (28) . Active MASP-3cf was further purified on a YMC-Q30 column the same way as described above for the proenzyme. High purity active MASP-3cf was eluted as the first major peak at about 150 mM NaCl. The stable zymogen variants, MASP-1cf R448Q and MASP-2cf R444Q, were prepared as described (7, 29) . Human alpha-thrombin (Activity ≥2800 NIH units/mg protein, cat.
no. T-1063) and bovine cationic trypsin (Activity ~10000 BAEE units/mg protein, cat. no. T-8003)
were purchased from Sigma. FB and FD from human plasma were purchased from Merck (Calbiochem brand), and C3b was a gift from Prof. Mohamed R. Daha (Leiden University, Leiden,
The Netherlands). The MASP-1 specific SGMI-1 and the MASP-2 specific SGMI-2 inhibitors were prepared according to Héja et al. (30) . Blood was drawn from 7 healthy volunteers into Vacutainer serum tubes (BD Diagnostics) to produce fresh serum, and into Vacutainer citrate tubes (BD Diagnostics) to produce fresh plasma. After centrifugation serum samples were pooled and kept frozen in aliquots at -70 o C to produce normal human serum. Human plasma was also prepared by centrifugation, pooled, and kept at -70 o C in aliquots. Cy3-NHS ester and Cy5-NHS ester was purchased from GE Healthcare. Acetonitrile and ultrapure (LC-MS grade) water for mass spectrometric analysis were purchased from Merck (Darmstadt, Germany).
Human pro-FD expression and purification
The C-terminally poly-histidine-tagged (His 6 ) human pre-pro-FD encoding DNA was purchased as a synthetic gene from Entelechon GmbH (Regensburg, Germany). The coding sequence was manually codon optimized for expression in Sf9 cells taking into account the Spodoptera frugiperda codon usage frequencies found in the Codon Usage Database (http://www.kazusa.or.jp/codon/). The clone encodes the human signal peptide, the activation peptide and the mature human FD polypeptide chain followed by a His 6 -tag. The gene sequence and the translation are provided as a supplement (supplementary Table S1 ). NaCl linear gradient in the same buffer. During this chromatographic step two separable forms of pro-FD-H 6 were observed. The first eluted peak was designated as "A", and the second peak, the major form, was designated as "B". Fractions were assayed for purity by SDS-PAGE, and the appropriate fractions of the two forms were combined separately, then concentrated on 10-kDa cutoff concentrators to about 1 mg/mL and stored frozen in aliquots. The "B" form represents intact human pro-FD-H 6 (see the next section) and the term "pro-FD" will refer to this form unless otherwise stated. The concentration of pro-FD was calculated based on the extinction coefficient ε 280 = 28 460 M -1 cm -1 , and a molecular mass of 25.8 kDa.
Characterization of pro-FD by mass spectrometry
Initial MALDI-TOF mass spectrometry (MS) analysis exhibited that the "B" form is consistent with the molecular weight of pro-FD-H 6 , and the "A" form is degraded probably at the N-terminus (data not shown). The "B" form of recombinant human pro-FD was further analyzed by liquid chromatography (HPLC) coupled to electrospray (ESI) quadrupole time-of-flight (QTOF) mass spectrometry. 10 µL of the sample was desalted and separated without pretreatment using reversed phase chromatography on a Dionex U3000 RSLC system (Thermo Scientific, Dreieich, Germany).
The separation was performed on a Poroshell 300SB C18 column (1 mm × 75 mm; 5 µm particle 
Preparation of active FD from pro-FD and testing its activity
For producing active FD from its zymogen form, pro-FD was incubated with 1/1000 amount of trypsin (by weight) at 37 o C for 25 minutes in 20 mM NaH 2 PO 4 , ~300 mM NaCl, pH=6.8 buffer. 
Preparation and purification of Cy3-pro-FD and Cy5-FD
For fluorescent labeling pro-FD and FD we used Cy3 and Cy5 CyDye monoreactive NHS Esters (GE Healthcare). Dried dyes were dissolved to 1 mg/ml in anhydrous DMF (Merck), and stored frozen in aliquots. Labeling reactions were performed in 20 mM NaH 2 PO 4 , ~300 mM NaCl, pH=6. single-labeled proteins were combined, then concentrated on 10 kDa cutoff concentrators to 1 mg/mL and stored frozen in aliquots. The concentrations of Cy3-pro-FD, and Cy5-FD were calculated based on the extinction coefficients of Cy3 (ε 549nm = 150 000 M -1 cm -1 ), and Cy5 (ε 649nm = 250 000 M -1 cm -1 ), and a molecular masses of 26.5 or 25.9 kDa, respectively.
Cy3-labeled pro-FD cleavage in serum and plasma samples
Conversion of Cy3-labeled pro-FD into Cy3-FD in serum or plasma was monitored as follows. 5 µL of 1 mg/mL Cy3-pro-FD was added to 50 µL of normal human serum or citrated plasma and the mixtures were incubated at 37 o C for 24-26 hours. Samples were withdrawn at every hour in the first 8 hours then an overnight (24-26 h) sample was collected.
In order to test the contribution of the thrombin-content of serum to convert pro-FD into FD we added 1 mL of serum to a Vacuette Hirudin Blood Tube (Roche) containing more than 45 µg hirudin. Cy3-pro-FD conversion was tested on the same batch of hirudin-treated and untreated serum as above.
In order to test the impact of MASP inhibitors on pro-FD conversion into FD we added them 
Results

Expression and characterization of His-tagged human pro-FD
Human pre-pro-FD was expressed in insect cells using a baculovirus vector as described in the Materials and Methods. The construct contained the human signal sequence and a C-terminal His 6 -tag to aid purification. As previously described, insect cells produce predominantly pro-FD (21).
Under our expression conditions we obtained two major variants eluting in different peaks termed "A" and "B" during the last cation exchange step. Preliminary MALDI-TOF analysis exhibited that the "B" form is consistent with the molecular weight pro-FD-H 6 , and the "A" form is probably degraded (data not shown). Further analysis by HPLC-ESI-QTOF MS ( Fig. 1) showed that the molecular weight of the "B" form is consistent with an N-terminal propeptide sequence of APPRGR. In all subsequent experiments we used the "B" form of pro-FD-H 6 , hereafter simply termed as pro-FD. Since our major goal was to detect pro-FD activation by various serine proteases, which involves cleavage at the N-terminus, the small tag at the C-terminus most likely does not interfere with this reaction. We also converted our pro-FD into active FD by trace amounts of trypsin and purified it to remove the trypsin activity. The produced active enzyme cleaved FB-C3b in a similar fashion as the purchased control FD purified from human plasma (data not shown).
In vitro cleavage-rates of pro-FD by various proteases
Pro-FD can be very effectively activated by trypsin in vitro (21), therefore we also used bovine cationic trypsin as a highly active control protease in our assay system. Samples of pro-FD (10-20 µM) were treated with trypsin, thrombin, MASP-1cf, MASP-2cf, MASP-3cf, and also the proenzymic forms of all three MASPs at 37 o C. The cleaving enzymes were used at concentrations suitable to produce approximately 80% consumption of pro-FD in less than 3 hours, as determined from preliminary experiments. Aliquots containing 10 µg total pro-FD + FD were withdrawn at 30-40 minute periods, diluted 30-fold with ice-cold binding buffer and analyzed immediately on a small cation exchange column as described in the Materials and Methods. The peak corresponding to pro-FD gradually disappears while a new peak with increasing intensity corresponding to FD appears over time (Fig. 2) . Fitting the AUC (area under the curve) values of the pro-FD peak versus time ( Fig. 3 ) yielded k obs values for each reaction. Normalized by the enzyme concentrations the cleavage efficiencies can be compared, as summarized in Table I . The highest cleavage rate, by far, is produced by trypsin, whereas active MASP-1cf, MASP-2cf, MASP-3cf, and thrombin are fairly efficient activators of pro-FD. Proenzymic MASPs have either marginal (R448Q MASP-1cf), or no activity at all.
Cleavage rates of pro-FD in human serum and plasma
In order to model pro-FD cleavage in human blood we developed a novel experimental setup that is suitable to monitor pro-FD cleavage in a complex mixture. We labeled pro-FD with Cy3 dye and followed its cleavage in normal human serum or citrated plasma. In both cases Cy3-labeled pro-FD was added at 3.5 µM final concentration, and its cleavage was followed at 37 (Table II) . These data suggest that each MASP could be considered as a potential activator, but only if a significant proportion is already activated.
Cleavage of pro-FD in human serum and plasma in the presence of MASP inhibitors
Previously we have developed specific inhibitors for MASP-1 and MASP-2 (30). SGMI-1 is a specific MASP-1 inhibitor with a K i of about 7 nM, while SGMI-2 is a highly selective MASP-2 inhibitor with a K i of about 6 nM. We observed that SGMI-2 also inhibits MASP-3, although very poorly, with a K i of about 5 µM (6). We used these inhibitors at various concentrations to assess their effects on pro-FD activation in serum and plasma.
SGMI-1 did not affect the conversion of Cy3-pro-FD to Cy3-FD even at the highest concentration (15 µM) applied (Fig. 5 and Table III ) neither in plasma nor in serum. This experiment unambiguously rules out MASP-1 as a direct pro-FD activator. Since in vitro active MASP-1 is a potent pro-FD activator, these results also imply that there is no significant amount of active MASP-1 in resting blood.
At 100 nM, which is well above the K i for MASP-2, SGMI-2 had no effect at all and even 1 µM of SGMI-2 had only small effect ( Fig. 5 and Table III ). This ruled out MASP-2 as well as direct pro-FD activator. Although we applied SGMI-2 primarily because it inhibits MASP-2, calculations presented in Table II would imply that essentially all MASP-2 would have to be in the active form to produce the measured Cy3-pro-FD half-life in plasma. This is in contrast with the observation that MASP-2 circulates as a proenzyme in the blood (32) . So the results are coherent with all calculations and previous observations. However, to our surprise, at high (15 µM) inhibitor concentration SGMI-2 significantly slowed down Cy3-pro-FD conversion both in serum and plasma ( Fig. 5 and Table III ). The effect was more pronounced in plasma. The difference between serum and plasma can be explained by the effect of thrombin and possibly other coagulation enzymes, which are not inhibited by SGMI-2 (6).
On the other hand, the measured concentration dependence is highly consistent with the K i value of 5 µM of SGMI-2 for MASP-3 (6).
In summary, our experiments so far rule out MASP-1 and MASP-2 as physiological pro-FD activators in resting blood, suggesting that some other protease or proteases are responsible for this activity. Our observations are consistent with active MASP-3 to be such an enzyme, but also imply that for such a role significant portion of MASP-3 should be in active form even in resting blood.
These assumptions require further experiments to prove unambiguously.
Cleavage of pro-FD in human plasma in the presence exogenous MASPs
In order to further characterize the effect MASPs on pro-FD conversion into FD we added MASP1cf, MASP-2cf, or MASP-3cf to normal human plasma at 50-200 nM concentrations. Since we have shown before that only the active forms have considerable activity toward pro-FD (Tables I   and II) MASP-3 (12-13, 22) , in the activation of the alternative pathway led us to take a closer look at the impact of MASPs on pro-FD cleavage. For this purpose we already had highly purified recombinant catalytic fragments of all MASPs, both in proenzymic and active form, and highly selective inhibitors for MASP-1 and MASP-2.
We also needed pro-FD that we produced in the baculovirus insect cell expression system. It had been previously reported that in this expression system, pro-FD is released into the culture medium in two zymogen forms with respective activation peptides AAPPRGR and APPRGR (21) in a 2:1 ratio. The high mass resolution and accuracy attained by the ESI-QTOF approach enabled us to unambiguous identify the produced proteins. In our experiments, the vast majority of pro-FD purified from insect cell culture medium contained the APPRGR activation peptide. This finding is in agreement with the predicted signal peptide cleavage site (33) . Notably, contrary to what was found earlier, the other form having an additional N-terminal alanine (AAPPRGR) could be barely detected. It should be noted, however, that Yamauchi and colleagues seem to have used a shortened signal peptide (21) In order to model the physiologic situation, we measured the half-lives of labeled pro-FD in normal human plasma and serum. The half-life was shorter in serum indicating that coagulation enzymes, including thrombin, may be able to convert pro-FD into FD. In complement assays serum is used routinely. Our results indicate that one should be careful when drawing conclusion on the natural pro-FD activating capacity of an individual or model animal by using serum samples (23) (24) , as low-level activation of pro-FD might occur by backup enzymes in the serum even in the absence of the natural pro-FD activator of the resting blood. In this respect it is noteworthy that FD deficient mouse serum reconstituted to less than 1% of the normal FD level restored 23% of the alternative pathway activity (34) (15) .
In resting blood the coagulation cascade is not activated, and therefore plasma experiments may represent a better model for the normal physiological pro-FD conversion than serum experiments. Because labeled pro-FD was converted to FD in plasma with a half-life of about 5 hours, it is reasonable that a proteolytic activity exists in resting blood that converts pro-FD to FD.
The labeled pro-FD concentration that we used was 3.5 µM, because such high concentration was necessary for reliable detection. This value is significantly higher than the physiological FD concentration (80 nM) (15) , distorting unfavorably the enzyme to substrate ratio, therefore it is plausible that the pro-FD conversion rate in the circulation is higher providing a significantly shorter half-life than the measured approximately 5 hours. Another contributing factor could be the "buffer effect" of citrated plasma. It is also possible that in the presence of Ca 2+ the main converting enzyme has a higher activity. On the other hand, in plasma further activation of lectin-pathway proteases and coagulation enzymes above the baseline level can be excluded, therefore we used both serum and plasma in order to evaluate the effects of our MASP inhibitors.
When we added a MASP-1 specific inhibitor (SGMI-1, K i ~ 7 nM) to serum or plasma at 15 µM final concentration the pro-FD conversion rate was no different from the inhibitor-free values.
It is noteworthy that SGMI-1 inhibits both active (30) and proenzymic MASP-1 (7) . Based on these observations we unambiguously ruled out MASP-1 as a direct pro-FD activator in resting blood. If MASP-1 is somehow involved in pro-FD maturation, its contribution can only be indirect e.g. through MASP-3 activation (7, 13).
To our surprise, SGMI-2, a highly selective MASP-2 inhibitor with a K i of 6 nM, did slowdown pro-FD conversion both in serum and plasma, although only at high inhibitor concentration (15 µM). The effect was more pronounced in plasma. Here we became suspicious, because according to our calculations essentially all MASP-2 would have to be in the active form to produce a 5-hour half-life for labeled pro-FD in plasma. This is in sharp contrast with previous observations that MASP-2 exists in the proenzyme form in resting blood (32) . Importantly, SGMI-2 also inhibits MASP-3 (6), but only quite poorly with a K i of about 5 µM. When we examined how pro-FD cleavage rate in plasma depends on SGMI-2 concentration, we found that 1 µM SGMI-2 had a minor effect, and 100 nM SGMI-2 had no effect at all. This concentration dependence was more consistent with the involvement of an enzyme inhibited by SGMI-2 with a K i value in the micromolar range. We note that MASP-3 is such an enzyme. Nevertheless, based solely on these results, we cannot yet identify MASP-3 as the exclusive pro-FD activator in resting blood.
Experiments with exogenously added MASPs further support the idea that MASP-3 is the physiological pro-FD activator, as we demonstrated that among MASPs only MASP-3 was capable of reducing the half-life of labeled pro-FD is plasma.
Our observations support the view of Takahashi et al. (24, 35) and Iwaki et al. (13) , who proposed that MASP-3 acts as a pro-FD activator. In contrast to Iwaki et al (13) On the other hand, we have unambiguously demonstrated that at least one protease capable of activating pro-FD exists in normal human plasma. While further experiments are needed to unequivocally identify the physiological and perhaps exclusive pro-FD activator in resting blood, here we provided important evidences that activated MASP-3 is the likely candidate (Fig. 7) . mechanism is the one in resting blood, because in normal blood most FD is present in the active form. In deficiencies, where a patient has mostly pro-FD, the backup mechanisms might contribute to pro-FD activation in case of injury or infection, or in vitro when serum is used for complement assays for testing. The most likely candidate to activate pro-FD in resting blood is active MASP-3, but further experiments are needed to unambiguously prove this assumption. bovine trypsin b 1.5 ± 0.5 × 10
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